Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Multiple Sclerosis

  Free Subscription


1 Arch Phys Med Rehabil
1 BMC Neurol
2 J Immunol
1 J Neuroimmunol
1 J Neurol Neurosurg Psychiatry
3 Mult Scler
3 Neurology
2 PLoS One
2 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Arch Phys Med Rehabil

  1. GERA G, Fling BW, Horak FB
    Cerebellar White Matter Damage Is Associated with Postural Sway Deficits in People With Multiple Sclerosis.
    Arch Phys Med Rehabil. 2019 Aug 26. pii: S0003-9993(19)31002.
    PubMed     Text format     Abstract available

    BMC Neurol

  2. YSRRAELIT MC, Fiol MP, Pena FV, Vanotti S, et al
    Adaptation and validation of a Spanish version of the treatment burden questionnaire in patients with multiple sclerosis.
    BMC Neurol. 2019;19:209.
    PubMed     Text format     Abstract available

    J Immunol

  3. COLAMATTEO A, Maggioli E, Azevedo Loiola R, Hamid Sheikh M, et al
    Reduced Annexin A1 Expression Associates with Disease Severity and Inflammation in Multiple Sclerosis Patients.
    J Immunol. 2019 Aug 28. pii: jimmunol.1801683. doi: 10.4049/jimmunol.1801683.
    PubMed     Text format     Abstract available

  4. ENGLER JB, Heckmann NF, Jager J, Gold SM, et al
    Pregnancy Enables Expansion of Disease-Specific Regulatory T Cells in an Animal Model of Multiple Sclerosis.
    J Immunol. 2019 Aug 23. pii: jimmunol.1900611. doi: 10.4049/jimmunol.1900611.
    PubMed     Text format     Abstract available

    J Neuroimmunol

  5. BASNYAT P, Sumelahti ML, Lehtimaki T, Elovaara I, et al
    Gene expression profiles of TNF-like cytokine 1A (TL1A) and its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) in multiple sclerosis.
    J Neuroimmunol. 2019;335:577020.
    PubMed     Text format     Abstract available

    J Neurol Neurosurg Psychiatry

  6. DEIVA K, Huppke P, Banwell B, Chitnis T, et al
    Consistent control of disease activity with fingolimod versus IFN beta-1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS.
    J Neurol Neurosurg Psychiatry. 2019 Aug 29. pii: jnnp-2019-321124.
    PubMed     Text format     Abstract available

    Mult Scler

  7. BARIN L, Kamm CP, Salmen A, Dressel H, et al
    How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.
    Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955.
    PubMed     Text format     Abstract available

  8. WEBER E, Goverover Y, DeLuca J
    Beyond cognitive dysfunction: Relevance of ecological validity of neuropsychological tests in multiple sclerosis.
    Mult Scler. 2019;25:1412-1419.
    PubMed     Text format     Abstract available

  9. BRANDSTADTER R, Katz Sand I, Sumowski JF
    Beyond rehabilitation: A prevention model of reserve and brain maintenance in multiple sclerosis.
    Mult Scler. 2019;25:1372-1378.
    PubMed     Text format     Abstract available


  10. FAREZ MF, Correale J, Armstrong MJ, Rae-Grant A, et al
    Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2019 Aug 28. pii: WNL.0000000000008157.
    PubMed     Text format     Abstract available

  11. RUCK T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, et al
    Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Neurology. 2018 Nov 7. pii: WNL.0000000000006648.
    PubMed     Text format     Abstract available

  12. BAHEERATHAN A, McNamara C, Kalam S, Rane N, et al
    The utility of FDG-PET imaging in distinguishing PML-IRIS from PML in a patient treated with natalizumab.
    Neurology. 2018;91:572-573.
    PubMed     Text format    

    PLoS One

  13. HAREL Y, Kalron A, Menascu S, Magalashvili D, et al
    Cognitive function in multiple sclerosis: A long-term look on the bright side.
    PLoS One. 2019;14:e0221784.
    PubMed     Text format     Abstract available

  14. ISMAILOVA K, Poudel P, Parlesak A, Frederiksen P, et al
    Vitamin D in early life and later risk of multiple sclerosis-A systematic review, meta-analysis.
    PLoS One. 2019;14:e0221645.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  15. RUPRECHT K, Mayer J
    On the origin of a pathogenic HERV-W envelope protein present in multiple sclerosis lesions.
    Proc Natl Acad Sci U S A. 2019 Aug 27. pii: 1911703116.
    PubMed     Text format    

  16. KREMER D, Perron H, Kury P
    Reply to Ruprecht and Mayer: Unearthing genomic fossils in the pathogenesis of multiple sclerosis.
    Proc Natl Acad Sci U S A. 2019 Aug 27. pii: 1912315116.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.